Cutaneous squamous cell carcinoma treatment market

Cutaneous Squamous Cell Carcinoma Treatment Market, by Treatment (Surgical (Moh’s Micrographic Surgery (MMS) and Electrodessication or Curettage), Non-surgical (Chemotherapy, Topical Immune Response Modifiers, Radiotherapy, and Systemic Chemotherapy)), by Application (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Request Free Sample

Dec 2020
CMI4280
195 Pages
Excel & Pdf
Pharmaceutical

Summary

Cutaneous squamous cell carcinoma (cSCC) is a type of non-melanoma skin cancer (NMSC), which is the most frequently diagnosed skin cancer. Most of the cSCCs are localized and easily treatable, and according to the National Center for Biotechnology Information (NCBI), around 5% of patients experience local recurrence, whereas 4% might develop nodal metastases, and around 2% die due to this disease. Increasing incidence of cutaneous squamous-cell carcinoma is expected to boost the market growth. For instance, according to the Journal of the European Academy of Dermatology and Venereology, an article published in January 2019, reports that in the period 2007-2015, 76,474 people newly diagnosed with squamous-cell carcinoma (SCC) were registered in North Rhine?Westphalia (NRW), with an age?standardized incidence in 2015 of 54 in men, double the rate of 26 in women.

The global cutaneous squamous cell carcinoma treatment market is estimated to be valued at US$ 10,309.76 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).

Figure 1. Global Cutaneous Squamous Cell Carcinoma Treatment Market Share (%), by Region, 2020

The increasing product development and ongoing trials are expected to propel growth of the global cutaneous squamous cell carcinoma treatment market

Major players in the market are focused on drug development for cutaneous squamous cell carcinoma treatment, which is expected to boost the market growth over the forecast period. for instance, in May 2020, Regeneron Pharmaceuticals, Inc., and Sanofi A.S., collaboratively initiated the clinical trial and announced the longer-term results for Libtayo (cemiplimab-rwlc), PD-1 inhibitor from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (cSCC). The data were presented during the virtual 2020 American Society of Clinical Oncology (ASCO) annual meeting.

Cutaneous Squamous Cell Carcinoma Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2019	Market Size in 2020:	US$ 10,309.76 Mn
Historical Data for:	2016 to 2019	Forecast Period:	2020 to 2027
Forecast Period 2020 to 2027 CAGR:	7.2%	2027 Value Projection:	US$ 16,867.06 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Treatment: Surgical: Moh’s Micrographic Surgery (MMS), Electrodessication or Curettage. Non-surgical: Chemotherapy, Topical Immune Response Modifiers, Radiotherapy, Systemic Chemotherapy. By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Others.
Companies covered:	Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc.
Growth Drivers:	Rising incidence of cutaneous squamous-cell carcinoma Product development and ongoing trials for the treatment of cutaneous squamous-cell carcinoma
Restraints & Challenges:	Lack of standardization in guidelines Longer duration of the surgery and higher cost

Figure 2. Global Cutaneous Squamous Cell Carcinoma Treatment Market Share (%), by Treatment, 2020

Increasing approvals for cutaneous squamous cell carcinoma treatment in North America is expected to boost the market growth

North America is expected to hold dominant position in the global cutaneous squamous cell carcinoma treatment market, owing to increasing approvals for cutaneous squamous cell carcinoma treatment in this region. For instance, in June 2020, Merck & Co., Inc., a U.S.-based multinational pharmaceutical company received approval for pembrolizumab (KEYTRUDA) from the U.S. Food and Drug Administration (FDA). The drug is approved for the treatment of recurrent or metastatic cutaneous squamous cell carcinoma (cSCC), which is not curable by surgery or radiation.

Global Cutaneous Squamous Cell Carcinoma Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global Cutaneous Squamous Cell Carcinoma Treatment market during the forecast period.

Key Players

Major players operating in the global Cutaneous Squamous Cell Carcinoma Treatment market include Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others.

Table of Content

*Browse 40 market data tables and 35 figures on "Cutaneous Squamous Cell Carcinoma Treatment Market” - Global forecast to 2027

N/A

- Frequently Asked Questions -

What will be the compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

The global cutaneous squamous cell carcinoma treatment market is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).

What is the estimated market size of the global cutaneous squamous cell carcinoma market in 2020?

The global cutaneous squamous cell carcinoma treatment market is estimated to be valued at US$ 10,309.76 million in 2020.

What are the major drivers for cutaneous squamous cell carcinoma treatment market growth?

Rising incidence of cutaneous squamous cell carcinoma and ongoing clinical trials for the treatment of cutaneous squamous-cell carcinoma are favoring the market growth.

Which is the leading treatment segment in the global cutaneous squamous cell carcinoma treatment market?

Non-surgical segment is expected to be the leading treatment segment in the global cutaneous squamous cell carcinoma treatment market during the forecast period (2020-2027).

Which region held the largest market share in the global cutaneous squamous cell carcinoma treatment market?

North America cutaneous squamous cell carcinoma treatment market is expected to generate highest revenue share during the forecast period.

Which are the major players operating in the global cutaneous squamous cell carcinoma treatment market?

Major players operating in the global cutaneous squamous cell carcinoma treatment market include Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others.